Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases

2016 ◽  
Vol 46 (13) ◽  
pp. 1402-1408 ◽  
Author(s):  
Norihito Nakano ◽  
Tomokazu Kawaoka ◽  
Hiroshi Aikata ◽  
Fumi Honda ◽  
Yuki Nakamura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lymph Node ◽  
Complete Response ◽  
Short Term ◽  
Sorafenib Treatment

scholarly journals Complete Response after Short-Term Sorafenib Treatment in a Patient with Lymph Node Metastasis of Hepatocellular Carcinoma

2012 ◽  
Vol 5 (2) ◽  
pp. 380-384 ◽  
Author(s):  
Hajime Mizukami ◽  
Tatehiro Kagawa ◽  
Yoshitaka Arase ◽  
Fumio Nakahara ◽  
Kota Tsuruya ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Complete Response ◽  
Short Term ◽  
Sorafenib Treatment ◽  
Node Metastasis

The Role of Contrast-Enhanced Ultrasound in Guiding Radiofrequency Ablation of Hepatocellular Carcinoma

2015 ◽  
Vol 66 (2) ◽  
pp. 171-178 ◽  
Author(s):  
Andy K.W. Chan ◽  
Chris Hegarty ◽  
Darren Klass ◽  
Eric Yoshida ◽  
Stephen Chung ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Complete Response ◽  
Term Treatment ◽  
Contrast Enhanced Ultrasound ◽  
Short Term ◽  
Short Term Treatment ◽  
Contrast Enhanced ◽  
Enhanced Computed Tomography

Purpose The objective of the study was to determine the efficacy of contrast-enhanced ultrasound (CEUS) using ultrasound (US)-specific microbubbles in guiding radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). Methods A retrospective analysis of 50 patients with HCC treated with CEUS guided RFA using perflutren at our institution was performed. CEUS images were first compared to B-mode US images performed at the same RFA session to determine the ability of CEUS to increase the conspicuity of lesions. A qualitative score (1 = poor, 2 = fair, 3 = excellent) was used to grade the ability to visualize the lesions. The preprocedure CEUS images were then evaluated using the most recent prior contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI). The efficacy of the treatment was evaluated with short-term follow-up imaging (median 1 month) for presence of residual or recurrent disease. Results CEUS allows at least fair visualization (score ≥2) in 78% (reader 1) and 80% (reader 2) of the lesions not visualized by B-mode US, and 50% (reader 1) and 42% (reader 2) of the lesions poorly visualized by B-mode US. Lesion appearances on CEUS are largely concordant with those on CT or MRI: 88% for reader 1, 96% for reader 2. With CEUS-guided RFA, complete response was achieved in the vast majority of the lesions at short-term follow-up: 82% for reader 1, 94% for reader 2. Conclusions CEUS increases the conspicuity and provides better characterization of hypervascular HCC that are either not seen or poorly seen on B-mode US, and CEUS provides real-time guidance of RFA with good short-term treatment responses.

Complete Response under Sorafenib Treatment for Hepatocellular Carcinoma is Associated to Development of Dermatology Adverse Events

2016 ◽  
Vol 64 (2) ◽  
pp. S319
Author(s):  
Á. Díaz-González ◽  
J. Rimola ◽  
R. María ◽  
A. Darnell ◽  
M. Varela ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Adverse Events ◽  
Complete Response ◽  
Sorafenib Treatment

scholarly journals A case of advanced hepatocellular carcinoma with lymph node metastasis with complete response after TS-1® therapy

Kanzo ◽  
2008 ◽  
Vol 49 (5) ◽  
pp. 218-223 ◽  
Author(s):  
Kazuhisa Nakamura ◽  
Yoshihisa Sato ◽  
Kei Kawagoe ◽  
Shuhei Okuyama ◽  
Hiroyasu Matsuoka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Complete Response ◽  
Advanced Hepatocellular Carcinoma ◽  
Node Metastasis

scholarly journals Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment

2021 ◽  
pp. 610-615
Author(s):  
Seok Bae Kim
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lymph Node ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Treatment ◽  
Node Metastasis ◽  
Extended Right Hepatectomy ◽  
Subcarinal Lymph Node ◽  
The Right ◽  
Hands And Feet ◽  
Severe Fever

There are only 13 cases of complete remission after sorafenib use in advanced hepatocellular carcinoma (HCC) worldwide. We herein report a rarer case in which the patient was cured after only 20 days of sorafenib use. A 61-year-old male patient was diagnosed with a huge HCC. The mass occupied almost the whole of the right hepatic lobe and a portion of segment 4. We performed extended right hepatectomy for cure. However, 3.5-cm-sized subcarinal lymph node metastasis was detected at 15 months after operation. We prescribed sorafenib 400 mg bid for palliative treatment. The patient had severe fever, pain, and blisters on the hands and feet, so the patient stopped taking it after 20 days. Subcarinal lymph node disappeared on chest computed tomography after 3 months, and there was no evidence of recurrence for a year.

scholarly journals A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

2021 ◽  
Vol 9 ◽  
pp. 232470962110584
Author(s):  
Yukinobu Watanabe ◽  
Masahiro Ogawa ◽  
Yu Tamura ◽  
Seiichiro Suda ◽  
Masahiro Kaneko ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lymph Node ◽  
Partial Response ◽  
Lymph Node Metastases ◽  
Transcatheter Arterial Chemoembolization ◽  
Complete Response ◽  
Transient Growth ◽  
Continuous Administration ◽  
Node Metastases ◽  
Arterial Chemoembolization

A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Sign in / Sign up

Export Citation Format

Share Document